What is the evidence that pre‑treatment TPMT genotyping reduces the incidence of hepatotoxicity in patients starting azathioprine for IBD
Out of scope for this tool. The focus of this literature tool is the surgical management of IBD. For medical management and drug dosing, please see ChatIBD.com.
No. The retrieved evidence does not establish that pre-treatment TPMT genotyping reduces hepatotoxicity; the demonstrated benefit of TPMT-guided dosing is for hematologic events (myelosuppression), not liver injury 1. A case-control study and a meta-analysis found no correlation between TPMT gene polymorphisms and hepatic adverse events in IBD patients 2. 1–4
What is known: - In a controlled study, TPMT variant carriers identified pre-treatment and given a dose reduction had a tenfold reduction in hematologic adverse reactions, without loss of efficacy. 1 - Identifying TPMT variants and reducing dose significantly reduces hematologic events during thiopurine treatment of IBD. 1 - A case-control study and a meta-analysis failed to show any correlation between TPMT gene polymorphisms and hepatic adverse events in IBD patients. 2 - Hepatotoxicity is mechanistically linked to methylated metabolites (6-MMP), whereas low TPMT activity predisposes chiefly to accumulation of 6-TGN and myelotoxicity. 3,4
What is unknown / caveats: - One review notes reduced TPMT activity may lead to hepatotoxicity 5, while a case-control study and meta-analysis found no TPMT–hepatotoxicity correlation 2 - No retrieved study measured hepatotoxicity incidence as an outcome of pre-treatment genotyping - Guideline recommendations for pre-thiopurine TPMT testing are framed around preventing myelosuppression, not liver injury 6 - The excerpts contain conflicting mechanistic statements about whether TPMT activity relates to hepatotoxicity at all.
## References
1. Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet. 2018. PMID: 29512050.
2. Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol. 2021. PMID: 35069993.
3. Singh A, Bhardwaj A, Kaur H, Bawa A, Midha V, Sood A. Drug-induced liver injury in inflammatory bowel disease: Challenges in diagnosis and monitoring. World J Hepatol. 2025. PMID: 41479516.
4. Fousekis FS, Theopistos VI, Katsanos KH, Tsianos EV, Christodoulou DK. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Res. 2018. PMID: 29707074.
5. Fu L, Wang S, Wang Y, Zhang H. A rare case report: Myopathy related to the interaction between azathioprine and infliximab in the treatment of ulcerative colitis and ankylosing spondylitis. Clin Case Rep. 2024. PMID: 38799535.
6. Wine E, Aloi M, Van Biervliet S, Bronsky J, di Carpi JM, Gasparetto M, Gianolio L, Gordon H, Hojsak I, Hudson AS, Hussey S, van Limbergen J, Miele E, Norsa L, Olén O, Pellino G, van Rheenen P, de Ridder L, Russell RK, Shouval DS, Trindade E, Turner D, Wilson DC, Yerushalmy Feler A, Assa A. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. J Pediatr Gastroenterol Nutr. 2025;81(3):765-815. PMID: 40677018.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
---
_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._
Reviewer notes